Monopar to Participate in the Radiopharma Forum by the Lake 2023
June 21 2023 - 6:00AM
Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage
biopharmaceutical company focused on developing innovative
treatments for cancer patients, today announced that Chandler
Robinson, MD, Monopar’s Chief Executive Officer, will participate
in a panel discussion at the “Radiopharma Forum by the Lake” on
Monday June 26, 2023, at 6:15pm CT at the Chicago Club.
“We are excited to be a part of this event, which is bringing
together leaders in the radiopharma space, from drug development
companies to investors to isotope manufacturers to CDMO’s. We
intend to highlight our lead radiopharma program focused on the
novel target uPAR along with a linker that binds to actinium-225
with high affinity which we filed a patent on,” said Dr.
Robinson.
Due to favorable properties such as its long half-life, high
potency, and short distance of activity, actinium-225 (Ac-225) is
quickly emerging as a therapeutic isotope of choice. Monopar’s
filed patent relates to the novel finding that antibodies
conjugated to the linker PCTA can achieve nearly 100% binding to
Ac-225. The PCTA-antibody conjugates also appear to bind daughter
ions, such as Bi-213, with high affinity. This high affinity
binding may decrease the amount of Ac-225 and its daughter ions
that permanently detach from the antibody, which could potentially
reduce off-target toxicity and increase efficacy by enabling higher
effective dosing.
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical
company focused on developing innovative treatments for cancer
patients. Monopar's pipeline consists of camsirubicin (Phase 1b)
for the treatment of advanced soft tissue sarcoma; MNPR-101, a
late-stage preclinical antibody for radiopharmaceutical use in
advanced cancers; and MNPR-202, an early-stage camsirubicin analog
for various cancers. For more information,
visit: www.monopartx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. The words “may,” “will,” “could,” “would,” “should,”
“expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,”
“predict,” “project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Examples of these forward-looking statements
include statements concerning: that actinium-225 (Ac-225) is
quickly emerging as an isotope of choice; and that high affinity
binding may decrease the amount of Ac-225 and its daughter ions
that permanently detach from the antibody, which could potentially
reduce off-target toxicity and increase efficacy by enabling higher
effective dosing. The forward-looking statements involve risks and
uncertainties including, but not limited to: Ac-225 bound to an
antibody does not prove efficacious in preclinical and clinical
studies; and the Company’s inability to raise sufficient funds or
engage a partner to continue the camsirubicin clinical program
through and beyond the Phase 1b clinical trial and to further
develop MNPR-101-Zr with its collaboration partner if its
first-in-human trial is successful; the effects of general economic
and market conditions on Monopar’s operations and ability to raise
funds; and the significant general risks and uncertainties
surrounding the research, development, regulatory approval, and
commercialization of therapeutics. Actual results may differ
materially from those expressed or implied by such forward-looking
statements. Risks are described more fully in Monopar's filings
with the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Monopar undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were made.
Any forward-looking statements contained in this press release
represent Monopar’s views only as of the date hereof and should not
be relied upon as representing its views as of any subsequent
date.
CONTACT:
Monopar Therapeutics Inc. Investor RelationsKim
R. TsuchimotoChief Financial Officerkimtsu@monopartx.com
Follow Monopar on social media for updates: Twitter:
@MonoparTx LinkedIn: Monopar Therapeutics
Monopar Therapeutics (NASDAQ:MNPR)
Historical Stock Chart
From Apr 2024 to May 2024
Monopar Therapeutics (NASDAQ:MNPR)
Historical Stock Chart
From May 2023 to May 2024